Geron
Geron Corporation is an American commercial-stage biopharmaceutical enterprise developing first-in-class telomerase inhibitor therapeutics for hematologic malignancies. The company commercializes Rytelo (imetelstat), an FDA-approved telomerase inhibitor designed for the treatment of adult patients with lower-risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia. Principal revenues derive from commercial product sales of Rytelo prescription therapies directly to specialty pharmaceutical distributors and hospital networks, alongside strategic licensing royalties. Core end markets encompass hematology-oncology clinics, specialized cancer centers, and prescription anemia patients across North America and international markets. Geron holds a market-leading pioneer position as the developer of the world's first approved telomerase inhibitor therapy in oncology. The corporation is headquartered in Foster City, California, and its common stock trades on the Nasdaq Global Select Market.
2 of the funds FundTelligence covers report a position in Geron.
- Legal name
- Geron Corp
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 2
Funds holding Geron
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.04 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)